http://www.zibb.com/all/theme/cq/ImmunoGen+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Mon, 23 Nov 2009 23:33:01 GMTMon, 23 Nov 2009 23:33:01 GMT608831http://www.zibb.com/all/theme/cq/ImmunoGen+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.zibb.com/article/5688853/Amgen+Continues+to+Leverage+ImmunoGen+s+TAP+TechnologyImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Paylod (TAP) technology to develop anticancer therapeutics to an undisclosed target. This is the secondhttp://www.zibb.com/article/5688853/Amgen+Continues+to+Leverage+ImmunoGen+s+TAP+TechnologyImmunoGen IncorporatedMon, 23 Nov 2009 23:33:01 GMThttp://www.genengnews.com/news/bnitem.aspx?name=69043975Amgen licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target. Thihttp://www.genengnews.com/news/bnitem.aspx?name=69043975ImmunoGen IncorporatedFri, 20 Nov 2009 00:00:00 GMThttp://abcnews.go.com/Business/wireStory?id=9130636Immunogen develops cancer treatments using its Tumor-Activated Prodrug, or TAP, technology. The technology uses antibodies to deliver a killer agent to a cell. It is part of a larger movement to develop more accurate cancer therapies that can target and neutralize specific cells.http://abcnews.go.com/Business/wireStory?id=9130636ImmunoGen IncorporatedThu, 19 Nov 2009 21:42:05 GMThttp://www.newsvine.com/_news/2009/11/19/3520854-immunogen-licenses-technology-to-amgen-for-1mImmunoGen Inc. said Thursday that Amgen Inc. licensed rights to a second potential cancer-treatment from the company for $1 million upfront.http://www.newsvine.com/_news/2009/11/19/3520854-immunogen-licenses-technology-to-amgen-for-1mImmunoGen IncorporatedThu, 19 Nov 2009 21:41:40 GMThttp://www.xconomy.com/boston/2009/11/19/immunogen-nabs-1m-from-amgen/Waltham, MA-based ImmunoGen (NASDAQ: ]) said today that Amgen has purchased a second license to develop a treatment that uses ImmunoGen's technology for linkinghttp://www.xconomy.com/boston/2009/11/19/immunogen-nabs-1m-from-amgen/ImmunoGen IncorporatedThu, 19 Nov 2009 21:14:14 GMThttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3600391&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=3600391&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2318139661%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBiotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directoryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3600391&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=3600391&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2318139661%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comImmunoGen IncorporatedMon, 09 Nov 2009 11:33:00 GMThttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=9389ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that its presentation at the Oppenheimer 20th Annual Healthcare Conference will be webcast live. The presentation is scheduled to begihttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=9389ImmunoGen IncorporatedTue, 27 Oct 2009 01:00:00 GMThttp://www.newratings.com/en/main/company_headline.m?id=1973890NEW YORK, October 8 (newratings.com) - Analysts at Brean Murray initiate coverage of Immunogen (ticker: IMGN) with a "buy" rating. The target price is set to $14. [more]http://www.newratings.com/en/main/company_headline.m?id=1973890ImmunoGen IncorporatedThu, 08 Oct 2009 17:58:25 GMThttp://www.biospace.com/news_story.aspx?StoryID=156292&full=1Daniel Junius, President and Chief Executive Officer, commented, “Amgen has an established track record of success in oncology and an expanding presence in antibody-based therapeutics.http://www.biospace.com/news_story.aspx?StoryID=156292&full=1ImmunoGen IncorporatedThu, 17 Sep 2009 12:00:00 GMThttp://boston.bizjournals.com/boston/stories/2009/09/14/daily43.html?ana=from_rssImmunoGen Inc., a developer of potential cancer therapies, will receive up to $35 million, plus royalties, from California-based Amgen Inc. in an exclusive licensing deal.http://boston.bizjournals.com/boston/stories/2009/09/14/daily43.html?ana=from_rssImmunoGen IncorporatedThu, 17 Sep 2009 00:00:00 GMThttp://seekingalpha.com/article/134432-immunogen-inc-f3q09-quarter-end-03-31-09-earnings-call-transcript?source=feedImmunoGen, Inc (IMGN)F3Q09 (Quarter End 03/31/09) Earnings CallApril 30, 2009 4:30 pm ETComplete Story <ahttp://seekingalpha.com/article/134432-immunogen-inc-f3q09-quarter-end-03-31-09-earnings-call-transcript?source=feedImmunoGen IncorporatedFri, 01 May 2009 01:05:35 GMThttp://www.businessweek.com/investor/content/oct2008/pi20081021_271215.htm?campaign_id=rss_nullThe small biotech outfit has joined with several marquee drugmakers in its program to develop cancer therapeutics.http://www.businessweek.com/investor/content/oct2008/pi20081021_271215.htm?campaign_id=rss_nullImmunoGen IncorporatedWed, 22 Oct 2008 04:01:00 GMThttp://us.rd.yahoo.com/finance/external/pssa/rss/SIG=12c7kruto/*http://seekingalpha.com/article/86007-is-pfizer-the-cure-for-a-weak-market?source=yahooMy friends, we are in tumultuous times. Markets are seemingly in freefall. During these times, the need for information surges. Blog viewership…through the roof. Google (GOOG) queries on all things financial…popping. Barrons…a bear on the front page.http://us.rd.yahoo.com/finance/external/pssa/rss/SIG=12c7kruto/*http://seekingalpha.com/article/86007-is-pfizer-the-cure-for-a-weak-market?source=yahooImmunoGen IncorporatedMon, 21 Jul 2008 18:07:11 GMThttp://www.forbes.com/healthcare/2008/06/23/immunogen-ziff-closer-markets-equity-cx_lal_0623markets33.html?feed=rss_business_healthcareThe heirs to the Ziff-Davis publishing fortune bit into a small biopharma company on Monday, adding ImmunoGen to their investment portfolio. Do they see the company as a takeover candidate or merely a good long-term investment?http://www.forbes.com/healthcare/2008/06/23/immunogen-ziff-closer-markets-equity-cx_lal_0623markets33.html?feed=rss_business_healthcareImmunoGen IncorporatedMon, 23 Jun 2008 19:00:00 GMThttp://www.contractpharma.com/news/2008/05/28/immunogen_selects_cytovance_to_manufacture_antibodyImmunoGen, Inc. has selected Cytovance Biologics for process development, cell banking and cGMP manufacturing of a proprietary ImmunoGen antibody. Cytovance will use its 44,000-sq.-ft., multi-product cGMP production facility in Oklahoma City, OK for the project.http://www.contractpharma.com/news/2008/05/28/immunogen_selects_cytovance_to_manufacture_antibodyImmunoGen IncorporatedWed, 28 May 2008 14:19:00 GMThttp://www.masshightech.com/stories/2008/04/07/daily41-Biogen-Icahn-lawsuit-is-attempt-to-force-a-sale.htmlBiogen Idec Inc. confirmed reports that billionaire investor Carl Icahn has filed a lawsuit against the Cambridge biotech company as a ploy to gain access to documents related to the failed sale of Biogen last year.http://www.masshightech.com/stories/2008/04/07/daily41-Biogen-Icahn-lawsuit-is-attempt-to-force-a-sale.htmlImmunoGen IncorporatedThu, 10 Apr 2008 12:51:13 GMThttp://www.icis.com/Articles/2005/02/11/651244/biogen-idec-has-positive-4q-and-immunogen-posts-results.htmlBiogen Idec, recently counted among the world’s largest biotechnology companies, reported positive fourth-quarter results, but came up slightly short of analyst expectations.http://www.icis.com/Articles/2005/02/11/651244/biogen-idec-has-positive-4q-and-immunogen-posts-results.htmlImmunoGen IncorporatedFri, 11 Feb 2005 20:27:35 GMThttp://www.dddmag.com/news-ImmunoGen-Announces-Start-of-IMGN388.aspxImmunoGen, Inc. announced the start of patient dosing in a Phase I clinical trial evaluating the company's IMGN388 targeted anticancer compound for the treatment of solid tumors.http://www.dddmag.com/news-ImmunoGen-Announces-Start-of-IMGN388.aspxImmunoGen Incorporatedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=Genentech+Inc+&Image=&newsid={46923AA9-4B2F-4FC3-872D-C88A5490A5E5}&symb=DNA&sid=152290WALTHAM, Mass., Mar 02, 2009 (BUSINESS WIRE) -- ImmunoGen, Inc. (NASDAQ GM:IMGN) , a biopharmaceutical company that develops targeted anticancer therapeutics, today announced several favorable developments related to T-DM1.http://www.holdrs.com/holdrs/main/index.asp?Action=Article&Description=Genentech+Inc+&Image=&newsid={46923AA9-4B2F-4FC3-872D-C88A5490A5E5}&symb=DNA&sid=152290ImmunoGen Incorporatedhttp://topics.nytimes.com/top/news/business/companies/immunogen-inc/index.htmlThe drug is undergoing clinical testing. About 100 of the company's 180 employees will lose their jobs, the company said. In addition to the layoffs, senior management will take a...http://topics.nytimes.com/top/news/business/companies/immunogen-inc/index.htmlImmunoGen Incorporatedhttp://www.smartbrief.com/news/bio/companyData.jsp?companyId=3873&c=pr2005PRNewswire | 5 days 1 hour 56 minutes ago DALLAS, Feb. 2 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.http://www.smartbrief.com/news/bio/companyData.jsp?companyId=3873&c=pr2005ImmunoGen Incorporatedhttp://www.boehringer-ingelheim.ca/news_releases/2001/2001-11-28.aspUnder the terms of the agreement, Boehringer Ingelheim will receive exclusive worldwide rights to commercialize maytansinoid TAPs using antibodies targeting CD44.http://www.boehringer-ingelheim.ca/news_releases/2001/2001-11-28.aspImmunoGen Incorporatedhttp://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-06-2000/0001305338&EDATE=Multi-Product Collaboration to Combine ImmunoGen's Tumor-Activated Prodrug Technology With Abgenix's Fully Human Antibodies CAMBRIDGE, Mass. and FREMONT, Calif., Sept. 6 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN) and Abgenix, Inc.http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-06-2000/0001305338&EDATE=ImmunoGen Incorporatedhttp://www.zibb.com/article/5682471/ImmunoGen+Inc+Announces+Second+License+Taken+by+Amgen+for+Right+to+Use+the+Company+s+TAP+TechnologyImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosedhttp://www.zibb.com/article/5682471/ImmunoGen+Inc+Announces+Second+License+Taken+by+Amgen+for+Right+to+Use+the+Company+s+TAP+TechnologyImmunoGen IncorporatedThu, 19 Nov 2009 16:01:00 GMThttp://www.zibb.com/article/5679907/ImmunoGen+Inc+IMGN+Corporate+Event+Announcement+NoticeImmunoGen, Inc. (IMGN) Expected next earnings release: Announcement date: 1/28/2010 - After Market Earnings Quarter: Q2 Announcement Status: Unconfirmed Expected next investor conference call information: Conference Call Date: 1/28/2010 Conference Call Time (ET): 4:30 PM Conference Call URL:http://www.zibb.com/article/5679907/ImmunoGen+Inc+IMGN+Corporate+Event+Announcement+NoticeImmunoGen IncorporatedWed, 18 Nov 2009 21:00:26 GMT